ArticleJournal of Cancer2019
miR-1307-3p Stimulates Breast Cancer Development and Progression by Targeting SMYD4.
Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 73 citations in OpenAlex.
- Whole blood miRNA expression signatures as predictors of neoadjuvant chemotherapy response in triple-negative breast cancer.Hereditas · 2026Article
- Machine Learning-Based Identification of Candidate Serum miRNA Features for Pan-Cancer and Cancer Type Classification.Life (Basel, Switzerland) · 2026Article
- Subtype-Specific mInternational journal of molecular sciences · 2026Article
- SMYD4 promotes MYH9 ubiquitination through lysine monomethylation modification to inhibit breast cancer progression.Breast cancer research : BCR · 2025Article
- Selective arm-usage of pre-miR-1307 dysregulates angiogenesis and affects breast cancer aggressiveness.BMC biology · 2025Article
- Whole‑exome sequencing insights into synchronous bilateral breast cancer with discordant molecular subtypes.Oncology letters · 2024Article
- MicroRNA-1307-3p contributes to breast cancer progression through PRM2.Thoracic cancer · 2024Article
- SMYD family in cancer: epigenetic regulation and molecular mechanisms of cancer proliferation, metastasis, and drug resistance.Experimental & molecular medicine · 2024Review
- Identification and validation of screening models for breast cancer with 3 serum miRNAs in an 11,349 samples mixed cohort.Breast cancer (Tokyo, Japan) · 2024Article
- Identification and validation of basement membrane-associated gene AGRN as prognostic and immune-associated biomarkers in colorectal cancer patients.Journal of cellular and molecular medicine · 2024Article
- Genetic Alterations ofInternational journal of molecular sciences · 2024Article
- MicroRNA Expression Profile in Early-Stage Breast Cancers.MicroRNA (Shariqah, United Arab Emirates) · 2024Article
- Tumor-suppressive functions of protein lysine methyltransferases.Experimental & molecular medicine · 2023Review
- Circulating miRNAs signature on breast cancer: the MCC-Spain project.European journal of medical research · 2023Article
- Multiomics dynamic learning enables personalized diagnosis and prognosis for pancancer and cancer subtypes.Briefings in bioinformatics · 2023Article
- Targeting Epigenetic Changes Mediated by Members of the SMYD Family of Lysine Methyltransferases.Molecules (Basel, Switzerland) · 2023Review
- SMYD Family Members Serve as Potential Prognostic Markers and Correlate with Immune Infiltrates in Gastric Cancer.Journal of oncology · 2023Article
- "Silicon-On-Insulator"-Based Biosensor for the Detection of MicroRNA Markers of Ovarian Cancer.Micromachines · 2022Article
- MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.Molecular medicine (Cambridge, Mass.) · 2022Review
- Engineered exosome-mediated delivery of circDIDO1 inhibits gastric cancer progression via regulation of MiR-1307-3p/SOCS2 Axis.Journal of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies show that dysregulated miRNAs play an important role in breast cancer initiation and progression. Here, we identified upregulated expression of miR-1307-3p in breast cancer tissues and that increased level of miR-1307-3p was closely correlated with lower survival rate in breast cancer patients. Consistent with clinical data, our
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.